Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.

KBC Group NV lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 24.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...

Equities research analysts at Leerink Partnrs reduced their FY2024 earnings per share estimates for Neurocrine Biosciences in ...

Visa and Abbott are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These products and services ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

UBS raised the firm’s price target on Neurocrine (NBIX) to $176 from $162 and keeps a Buy rating on the shares. The firm expects Neurocrine to ...

Mizuho Securities analyst Uy Ear has maintained their neutral stance on NBIX stock, giving a Hold rating on January 21.Invest with Confidence: ...

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...